Portage Biotech (NASDAQ:ALP) Insider Fiorenzo Villani Purchases 4,265 Shares

Portage Biotech Inc. (NASDAQ:ALP) insider Fiorenzo Villani acquired 4,265 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were purchased at an average price of $4.05 per share, with a total value of $17,273.25. Following the completion of the transaction, the insider owned 38,886 shares of the company’s stock, valued at $157,488.30. The trade was a 12.32% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Fiorenzo Villani also recently made the following trade(s):

• On Tuesday, September 15th, Fiorenzo Villani purchased 7,900 shares of Portage Biotech stock. The shares were purchased at an average price of $4.15 per share, with a total value of $32,785.00.
• On Tuesday, September 15th, Fiorenzo Villani purchased 10,382 shares of Portage Biotech stock. The shares were purchased at an average cost of $4.07 per share, for a total transaction of $42,254.74.
• On Monday, September 14th, Fiorenzo Villani acquired 2,000 shares of Portage Biotech stock. The stock was acquired at an average price of $4.16 per share, for a total transaction of $8,320.00.
• On Wednesday, September 9th, Fiorenzo Villani acquired 7,000 shares of Portage Biotech stock. The stock was acquired at an average price of $5.07 per share, with a total value of $35,490.00.

Portage Biotech Trading Up 9.8%

ALP stock traded up $0.40 during midday trading on Thursday, hitting $4.50. 53,755 shares of the company’s stock were exchanged, compared to its average volume of 232,688. Portage Biotech Inc. has a 1-year low of $3.20 and a 1-year high of $690.00. The company has a current ratio of 0.31, a quick ratio of 0.31 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $6.97 million, a PE ratio of -0.01 and a beta of 0.54. The business has a 50-day simple moving average of $9.78 and a two-hundred day simple moving average of $14.39.

Portage Biotech (NASDAQ:ALP) last announced its quarterly earnings results on Thursday, July 16th. The company reported $23.75 EPS for the quarter. The business had revenue of $0.05 million during the quarter. On average, sell-side analysts predict that Portage Biotech Inc. will post -14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ALP. HC Wainwright began coverage on shares of Portage Biotech in a research note on Monday, August 17th. They set a “neutral” rating and a $12.50 target price for the company. Wall Street Zen upgraded shares of Portage Biotech to a “hold” rating in a report on Saturday, September 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Portage Biotech in a research report on Friday, July 24th. Finally, Zacks Research upgraded shares of Portage Biotech to a “hold” rating in a report on Tuesday, August 18th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $12.50.

About Portage Biotech

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.